{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:04:29Z","timestamp":1789610669801,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Shandong Province","award":["ZR2020MH226"],"award-info":[{"award-number":["ZR2020MH226"]}]},{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202312378"],"award-info":[{"award-number":["tsqn202312378"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972793"],"award-info":[{"award-number":["81972793"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02332-6","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:43:40Z","timestamp":1782816220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring LTB-mediated T cell differentiation as a prognostic marker in triple-negative breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Xuekai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxiao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-9201","authenticated-orcid":false,"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"2","key":"2332_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176\u201398.","journal-title":"Cancer Discov"},{"issue":"1","key":"2332_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2332_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"2332_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361\u201370.","journal-title":"Cancer Immunol Res"},{"key":"2332_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.breast.2016.07.015","volume":"29","author":"S Luen","year":"2016","unstructured":"Luen S, Virassamy B, Savas P, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241\u201350.","journal-title":"Breast"},{"key":"2332_CR6","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418): 61\u201370.","DOI":"10.1038\/nature11412"},{"issue":"1","key":"2332_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2332_CR8","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688\u201398.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2332_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428\u201340.","journal-title":"Cancer Cell"},{"issue":"4","key":"2332_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","volume":"13","author":"P Savas","year":"2016","unstructured":"Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228\u201341.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2332_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13058-019-1148-6","volume":"21","author":"P Jezequel","year":"2019","unstructured":"Jezequel P, Kerdraon O, Hondermarck H, et al. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. Breast Cancer Res. 2019;21(1):65.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2332_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/modpathol.2017.126","volume":"31","author":"TA Adams","year":"2018","unstructured":"Adams TA, Vail PJ, Ruiz A, et al. Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. Mod Pathol. 2018;31(2):288\u201398.","journal-title":"Mod Pathol"},{"issue":"1","key":"2332_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"key":"2332_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"2332_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1743222","volume":"17","author":"L Xiang","year":"2026","unstructured":"Xiang L, Rao J, Ma A, et al. Integrating bulk, single-cell, and spatial transcriptomics to identify a novel pyroptosis-related gene signature for predicting prognosis and tumor immune landscape in triple-negative breast cancer. Front Immunol. 2026;17:1743222.","journal-title":"Front Immunol"},{"key":"2332_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106936","volume":"107","author":"Y Zou","year":"2022","unstructured":"Zou Y, Xie J, Zheng S, et al. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg. 2022;107:106936.","journal-title":"Int J Surg"},{"key":"2332_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194883","author":"M Schmidt","year":"2021","unstructured":"Schmidt M, Heimes AS. Immunomodulating therapies in breast cancer-from prognosis to clinical practice. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13194883.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2332_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00262-019-02437-2","volume":"69","author":"Y Romero","year":"2020","unstructured":"Romero Y, Wise R, Zolkiewska A. Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells. Cancer Immunol Immunother. 2020;69(1):43\u201355.","journal-title":"Cancer Immunol Immunother"},{"key":"2332_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41523-020-0155-1","volume":"6","author":"J Hudecek","year":"2020","unstructured":"Hudecek J, Voorwerk L, van Seijen M, et al. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ Breast Cancer. 2020;6:15.","journal-title":"NPJ Breast Cancer"},{"issue":"15","key":"2332_CR20","doi-asserted-by":"publisher","first-page":"e177555","DOI":"10.1172\/jci.insight.177555","volume":"9","author":"G Zhang","year":"2024","unstructured":"Zhang G, Feizi N, Zhao D, Halesha L, Williams AL, Randhawa PS, et al. Lymphotoxin \u03b2 receptor and tertiary lymphoid organs shape acute and chronic allograft rejection. JCI Insight. 2024;9(15):e177555.","journal-title":"JCI Insight"},{"issue":"1","key":"2332_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01947-5","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Jin S, Wang S, et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct Target Ther. 2024;9(1):225.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2332_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7150\/jca.17437","volume":"8","author":"S Kim","year":"2017","unstructured":"Kim S, Park S, Cho MS, et al. Strong correlation of Indoleamine 2,3-Dioxygenase 1 expression with basal-like phenotype and increased lymphocytic infiltration in triple-negative breast cancer. J Cancer. 2017;8(1):124\u201330.","journal-title":"J Cancer"},{"key":"2332_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.679517","volume":"11","author":"P Li","year":"2021","unstructured":"Li P, Wu R, Li K, et al. IDO inhibition facilitates antitumor immunity of V\u03b39V\u03b42 T cells in triple-negative breast cancer. Front Oncol. 2021;11:679517.","journal-title":"Front Oncol"},{"issue":"10","key":"2332_CR24","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41379-018-0061-3","volume":"31","author":"EA Dill","year":"2018","unstructured":"Dill EA, Dillon PM, Bullock TN, et al. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Mod Pathol. 2018;31(10):1513\u201322.","journal-title":"Mod Pathol"},{"key":"2332_CR25","doi-asserted-by":"crossref","unstructured":"Mamoor S. Differential expression of integral membrane protein 2A in cancers of the breast. 2021.","DOI":"10.31219\/osf.io\/c6jpw"},{"issue":"1","key":"2332_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/CBM-200006","volume":"30","author":"Q Zeng","year":"2021","unstructured":"Zeng Q, Li L, Feng Z, et al. LCP1 is a prognostic biomarker correlated with immune infiltrates in gastric cancer. Cancer Biomark. 2021;30(1):105\u201325.","journal-title":"Cancer Biomark"},{"issue":"4","key":"2332_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.31083\/j.fbl2704127","volume":"27","author":"K Murayama","year":"2022","unstructured":"Murayama K, Matsuda H. Detection of biomarkers for epithelial-mesenchymal transition with single-cell trajectory inference. Front Biosci (Landmark Ed). 2022;27(4):127.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"10","key":"2332_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/cmi.2017.13","volume":"14","author":"H Tang","year":"2017","unstructured":"Tang H, Zhu M, Qiao J, et al. Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cell Mol Immunol. 2017;14(10):809\u201318.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"2332_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.immuni.2012.06.010","volume":"37","author":"C Benezech","year":"2012","unstructured":"Benezech C, Mader E, Desanti G, et al. Lymphotoxin-beta receptor signaling through NF-kappaB2-RelB pathway reprograms adipocyte precursors as lymph node stromal cells. Immunity. 2012;37(4):721\u201334.","journal-title":"Immunity"},{"issue":"1","key":"2332_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12964-019-0460-1","volume":"17","author":"M Banach-Orlowska","year":"2019","unstructured":"Banach-Orlowska M, Wyszynska R, Pyrzynska B, et al. Cholesterol restricts lymphotoxin beta receptor-triggered NF-kappaB signaling. Cell Commun Signal. 2019;17(1):171.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"2332_CR31","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.cllc.2020.07.016","volume":"22","author":"MS Oh","year":"2021","unstructured":"Oh MS, Guzner A, Wainwright DA, et al. The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Clin Lung Cancer. 2021;22(1):e57\u201362.","journal-title":"Clin Lung Cancer"},{"key":"2332_CR32","doi-asserted-by":"crossref","unstructured":"Oreskovic E, Wheeler EC, Mengwasser KE, et al. Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1. Proc Natl Acad Sci USA. 2022;119(7).","DOI":"10.1073\/pnas.2120540119"},{"key":"2332_CR33","doi-asserted-by":"crossref","unstructured":"Kim C, Yu Y S, Park J Y, et al. 126 Prognostic gene signature reflecting CD8+ T cell enrichment in early-stage triple-negative breast cancer. J ImmunoTherapy Cancer. 2022; 10(Suppl 2): A139\u2013A.","DOI":"10.1136\/jitc-2022-SITC2022.0126"},{"key":"2332_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186968","author":"M Oshi","year":"2020","unstructured":"Oshi M, Asaoka M, Tokumaru Y, et al. CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21186968.","journal-title":"Int J Mol Sci"},{"key":"2332_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003427","author":"CK Anders","year":"2022","unstructured":"Anders CK, Woodcock MG, Van Swearingen AED, et al. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003427.","journal-title":"J Immunother Cancer"},{"issue":"21","key":"2332_CR36","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2332_CR37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12967-023-04486-9","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xie B, Chen Q. RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment. J Transl Med. 2023;21(1):595.","journal-title":"J Transl Med"},{"issue":"4","key":"2332_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1074-7613(02)00423-5","volume":"17","author":"E Dejardin","year":"2002","unstructured":"Dejardin E, Droin NM, Delhase M, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity. 2002;17(4):525\u201335.","journal-title":"Immunity"},{"key":"2332_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aak9679.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2332_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.immuni.2005.10.002","volume":"23","author":"JL Browning","year":"2005","unstructured":"Browning JL, Allaire N, Ngam-Ek A, et al. Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity. 2005;23(5):539\u201350.","journal-title":"Immunity"},{"key":"2332_CR41","doi-asserted-by":"crossref","unstructured":"Hua Y, Vella G, Rambow F, et al. Anticancer immunotherapies transition postcapillary venules into high-endothelial venules that generate TCF1+ T lymphocyte niches through a feed-forward loop. 2021.","DOI":"10.1101\/2021.12.24.474088"},{"key":"2332_CR42","doi-asserted-by":"crossref","unstructured":"Mamoor S. Lymphotoxin beta is differentially expressed in central nervous system metastasis. 2023.","DOI":"10.31219\/osf.io\/pqdsn"},{"issue":"5","key":"2332_CR43","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/cbdd.12348","volume":"84","author":"H Yang","year":"2014","unstructured":"Yang H, He X, Zheng Y, et al. Down-regulation of asparagine synthetase induces cell cycle arrest and inhibits cell proliferation of breast cancer. Chem Biol Drug Des. 2014;84(5):578\u201384.","journal-title":"Chem Biol Drug Des"},{"issue":"3","key":"2332_CR44","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/cr.2018.15","volume":"28","author":"Q Wang","year":"2018","unstructured":"Wang Q, Jiang J, Ying G, et al. Tamoxifen enhances stemness and promotes metastasis of ERalpha36(+) breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res. 2018;28(3):336\u201358.","journal-title":"Cell Res"},{"issue":"25","key":"2332_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202001705","volume":"16","author":"AM Vargason","year":"2020","unstructured":"Vargason AM, Santhosh S, Anselmo AC. Surface modifications for improved delivery and function of therapeutic bacteria. Small. 2020;16(25):e2001705.","journal-title":"Small"},{"key":"2332_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.611802","volume":"8","author":"HY Cho","year":"2020","unstructured":"Cho HY, Choi JH, Kim KJ, et al. Microfluidic system to analyze the effects of interleukin 6 on lymphatic breast cancer metastasis. Front Bioeng Biotechnol. 2020;8:611802.","journal-title":"Front Bioeng Biotechnol"},{"issue":"7","key":"2332_CR47","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367.","journal-title":"J Clin Invest"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02332-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02332-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02332-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:46:03Z","timestamp":1789609563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02332-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2332"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02332-6","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study involving human PBMCs and associated databases has been approved by the Institutional Review Board of the Shandong Provincial Second General Hospital (No. XYK20221202).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"157"}}